PMID- 37282609
OWN - NLM
STAT- MEDLINE
DCOM- 20230727
LR  - 20230810
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 129
IP  - 16
DP  - 2023 Aug 15
TI  - Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain 
      (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with 
      a poor clinical outcome in multiple myeloma.
PG  - 2491-2498
LID - 10.1002/cncr.34895 [doi]
AB  - BACKGROUND: Chromosome 1 abnormalities in multiple myeloma (MM) are increasingly 
      recognized as high risk-defining features. The authors report the prognostic 
      value of del(1p13.3) by fluorescence in situ hybridization (FISH) at enrollment 
      in subjects treated on total therapy clinical trials 2-6. METHODS: FISH probes 
      were generated from specific BAC DNA clones for the AHCYL1 gene locus (1p13.3) 
      and the CKS1B locus (1q21). RESULTS: A total of 1133 patients were included in 
      this analysis. Although del(1p13.3) was detected in 220 (19.4%) patients, 
      1q21gain or 1q21amp were observed in 300 (26.5%) and 150 (13.2%) patients, 
      respectively. Concomitant del(1p13.3) with 1q21 gain or amp was observed in 65 
      (5.7%) and 29 (2.5%) patients, respectively. There was enrichment of high-risk 
      features such as International Staging System (ISS) stage 3 disease and gene 
      expression profiling (GEP)70 high risk (HR) in the group with del(1p13.3). 
      Presence of del(1p13.3) confers inferior progression-free survival (PFS) and 
      overall survival (OS). On multivariate analysis, the presence of ISS stage 3 
      disease, GEP70 HR, 1q21gain, and 1q21amp were independent predictors of PFS or 
      OS. CONCLUSIONS: The PFS and OS of patients with combined abnormalities of del 
      (1p13.3)/1q21gain or amp was significantly worse compared to del(1p13.3) alone 
      and 1q21gain or 1q21 amp alone, which identifies a subset of patients with poor 
      clinical outcomes.
CI  - (c) 2023 American Cancer Society.
FAU - Mohan, Meera
AU  - Mohan M
AUID- ORCID: 0000-0002-6913-6526
AD  - Clinical Cancer Center, Division of Hematology Oncology, Medical College of 
      Wisconsin, Milwaukee, Wisconsin, USA.
FAU - Gong, Zimu
AU  - Gong Z
AD  - Baylor Scott & White Charles A. Sammons Cancer Center, Houston, Texas, USA.
FAU - Ashby, Timothy Cody
AU  - Ashby TC
AD  - Myeloma Center, Winthrop P. Rockefeller Institute, University of Arkansas for 
      Medical Sciences, Little Rock, Arkansas, USA.
FAU - Al Hadidi, Samer
AU  - Al Hadidi S
AUID- ORCID: 0000-0003-4297-8042
AD  - Myeloma Center, Winthrop P. Rockefeller Institute, University of Arkansas for 
      Medical Sciences, Little Rock, Arkansas, USA.
FAU - Thanendrarajan, Sharmilan
AU  - Thanendrarajan S
AD  - Myeloma Center, Winthrop P. Rockefeller Institute, University of Arkansas for 
      Medical Sciences, Little Rock, Arkansas, USA.
FAU - Schinke, Carolina
AU  - Schinke C
AD  - Myeloma Center, Winthrop P. Rockefeller Institute, University of Arkansas for 
      Medical Sciences, Little Rock, Arkansas, USA.
FAU - Alapat, Daisy
AU  - Alapat D
AD  - Department of Pathology, University of Arkansas for Medical Sciences, Little 
      Rock, Arkansas, USA.
FAU - Shaughnessy, John D Jr
AU  - Shaughnessy JD Jr
AD  - Myeloma Center, Winthrop P. Rockefeller Institute, University of Arkansas for 
      Medical Sciences, Little Rock, Arkansas, USA.
FAU - Zhan, Fenghuang
AU  - Zhan F
AD  - Myeloma Center, Winthrop P. Rockefeller Institute, University of Arkansas for 
      Medical Sciences, Little Rock, Arkansas, USA.
FAU - van Rhee, Frits
AU  - van Rhee F
AD  - Myeloma Center, Winthrop P. Rockefeller Institute, University of Arkansas for 
      Medical Sciences, Little Rock, Arkansas, USA.
FAU - Sawyer, Jeffery R
AU  - Sawyer JR
AD  - Myeloma Center, Winthrop P. Rockefeller Institute, University of Arkansas for 
      Medical Sciences, Little Rock, Arkansas, USA.
FAU - Tian, Erming
AU  - Tian E
AD  - Myeloma Center, Winthrop P. Rockefeller Institute, University of Arkansas for 
      Medical Sciences, Little Rock, Arkansas, USA.
FAU - Zangari, Maurizio
AU  - Zangari M
AD  - Myeloma Center, Winthrop P. Rockefeller Institute, University of Arkansas for 
      Medical Sciences, Little Rock, Arkansas, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230606
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
CIN - Cancer. 2023 Aug 15;129(16):2450-2452. PMID: 37282718
MH  - Humans
MH  - *Multiple Myeloma/therapy
MH  - In Situ Hybridization, Fluorescence
MH  - Chromosomes, Human, Pair 1/genetics
MH  - Chromosome Aberrations
MH  - Prognosis
MH  - Chromosome Deletion
OTO - NOTNLM
OT  - 1q21 gain and 1q21 amplification
OT  - Del(1p13.3)
OT  - chromosome 1 abnormalities
OT  - multiple myeloma
EDAT- 2023/06/07 06:42
MHDA- 2023/07/27 06:42
CRDT- 2023/06/07 03:46
PHST- 2023/01/18 00:00 [revised]
PHST- 2022/11/22 00:00 [received]
PHST- 2023/02/09 00:00 [accepted]
PHST- 2023/07/27 06:42 [medline]
PHST- 2023/06/07 06:42 [pubmed]
PHST- 2023/06/07 03:46 [entrez]
AID - 10.1002/cncr.34895 [doi]
PST - ppublish
SO  - Cancer. 2023 Aug 15;129(16):2491-2498. doi: 10.1002/cncr.34895. Epub 2023 Jun 6.